Product Description: Favipiravir-13C15N (T-705-13C15N) is 13C and 15N labeled Favipiravir. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
Applications: COVID-19-anti-virus
Formula: C4 13CH4FN2 15NO2
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Furuta Y, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54./[3]Rocha-Pereira J, et al. Favipiravir (T-705) inhibits in vitro norovirus replication.
Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80.
Molecular Weight: 159.09
Research Area: Infection
Target: Bacterial;DNA/RNA Synthesis;Influenza Virus;Isotope-Labeled Compounds;SARS-CoV
Deutsch
English
